Seaport Research analyst Walt Liptak raised the firm’s price target on Idex Corp. to $240 from $230 and keeps a Buy rating on the shares post the Q4 report. The analyst is encouraged by some early signs of recovery in the businesses, including biopharma getting a little better and some short cycle businesses doing well in January. The firm would continue to use pullbacks in the stock as buying opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IEX: